Perspectives on Coordinated Care: Tagraxofusp for BPDCN Through Shared-Care Models

EP: 1.A 74-Year-Old Patient Newly Diagnosed with BPDCN

EP: 2.Treatment Approaches for Non–Transplant Eligible Patients With BPDCN

EP: 3.Tagraxofusp: CD123-Targeted Therapy for Frontline Treatment of BPDCN

EP: 4.Key Insights for Managing Patients on Tagraxofusp Therapy for BPDCN

Now Viewing

EP: 5.Perspectives on Coordinated Care: Tagraxofusp for BPDCN Through Shared-Care Models

EP: 6.Future Directions in BPDCN Treatment

Summary for Physicians:

1. Structuring the Shared-Care Model Between Academic and Community Centers:

• Clear Roles: Define specific roles for academic and community centers to ensure complementary care.

• Communication: Foster regular communication (eg, case discussions, telemedicine) for collaboration and updates.

• Education: Academic centers provide training to keep community physicians informed on best practices.

• Shared Decision-Making: Involve both centers in patient care decisions for comprehensive management.

• Technology: Use electronic health records and telemedicine for seamless information exchange.

2. Monitoring TAG in the Community Setting:

• Blood Glucose: Regularly monitor fasting and postprandial glucose levels to assess therapy effectiveness.

• Kidney Function: Track renal parameters (eg, creatinine, estimated glomerular filtration rate) to detect any adverse effects.

• Adverse Effects: Watch for gastrointestinal issues or hypoglycemia and manage promptly.

• Comorbidities: Monitor for complications in patients with other conditions (eg, cardiovascular disease).

• Adherence: Ensure patients follow the TAG regimen through regular follow-ups and support.

These strategies ensure effective collaboration and safe use of TAG therapy in both academic and community settings.